-
(单词翻译:双击或拖选)
JUDY WOODRUFF: Now the last in our series on Ebola in West Africa — tonight, a look at new research to help stop or slow the next outbreak. The best hope may ultimately come from a new vaccine1.
Science correspondent Miles O'Brien reports, part of his series on Cracking Ebola's Code.
MILES O'BRIEN: It's dark and early in Freetown, Sierra Leone. A team of pharmacists is in a nondescript government building preparing the day's supply of an experimental vaccine against Ebola.
The clock starts running when they take the vaccine out of a very deep freeze. This is likely the coldest spot in the whole country. The vaccine can only be thawed2 out right before it is injected, or it will lose its potency3, and all of this will be a waste of time, money and hope.
WOMAN: The power went out.
MILES O'BRIEN: Another reminder5 of how hard it is to conduct a high-tech6 vaccine trial in one of the poorest countries on the planet. But they are ready. They have got two backup generators7 for the building, solar-charged batteries, and, if all else fails, a special container that maintains about 100 degrees below zero Fahrenheit8 for five days without power.
Pharmacist Morrison Jusu is delivering the vaccine three-and-a-half miles across Freetown. After a seemingly endless national nightmare, he carries a cooler full of expectations. He knows much is riding with him.
MORRISON JUSU, STRIVE Trial Research Team: Some people lost family members. And some families were essentially9 wiped out as a result of this thing. And if this vaccine proves out to be something that prevents such in the future, then it's — it's — words cannot describe how much relief that would be to this community.
MILES O'BRIEN: While Jusu and the vaccine are wending their way, a line is growing outside their destination, Freetown's Connaught Hospital.
The volunteers start showing up before dawn. They are health care workers. This trial is limited to them because they are, by far, the most at risk of contracting Ebola virus disease. Even though there is no evidence the vaccine poses any real danger, they must weigh the rumors10 and the uncertainties11.
MOHAMED SAMBOLA, Vaccine Trial Volunteer (through interpreter): Life is all about risks. But I believe it will be of help in the job that I do.
RUGIATU CONTEH, Vaccine Trial Volunteer (through interpreter): It is a high risk for me. I believe this can protect me from Ebola, and that's why I came here for this vaccine.
MILES O'BRIEN: It wasn't always this way. The trial got off to a slow start when it began in April. People were too afraid.
Dr. Mohamed Samai is one of the principal investigators12.
DR. MOHAMED SAMAI, College of Medicine and Allied13 Health Sciences: People said the vaccine was the Ebola virus, so, once you get it, you become infected. So, a lot of people were not willing to come forward there in the first week to take the vaccine, because they thought they should wait and see what happens.
MILES O'BRIEN: The vaccine does contain a piece of the Ebola virus, a protein. It's enough to trick the body into triggering its natural defenses, but won't give the recipient15 Ebola virus disease.
On the wall in the lobby of the hospital, a spontaneous memorial to some of the doctors and nurses who died here during the epidemic16, a grim reminder of what motivates volunteers like Richard Kanu.
RICHARD KANU, Vaccine Trial Volunteer (through interpreter): I became aware of it through my friends who got the shot three days ago. Since they're not having any side effects, I decided17 to come and have a go at it myself, because I feel it will protect me.
MILES O'BRIEN: Kanu works on a team that buries the highly contagious18 dead. He has been shunned19 by friends, even forced out of his own home.
RICHARD KANU (through interpreter): I will go back and tell them that I have had the vaccine and they should rest assured that I won't have the virus. I will probably encourage them to step forward as well.
MILES O'BRIEN: Bad traffic delays Jusu's ride to the hospital, but, when he arrives, the vaccine isn't spoiled, and the volunteers are ready. The nursing team doesn't waste any time prepping for the jabs.
Aruna Thorlie is a chlorine sprayer who disinfects Ebola treatment units.
Have you felt anything different? Did it hurt, anything?
ARUNA THORLIE, Vaccine Trial Volunteer (through interpreter): I feel the same as I did before. I hope and pray that it works.
MILES O'BRIEN: The vaccine is made by Merck. The trial is a partnership20 between the Sierra Leone Ministry21 of Health, the U.S. Centers for Disease Control and Prevention and the medical college in Freetown.
DR. MOHAMED SAMAI: Once we can document the effectiveness of the vaccine, and we are now sure that it can really protect them, we can move to another stage, where we will look at the community and the population at large.
MILES O'BRIEN: Across the border in Liberia, a separate trial is testing the same vaccine, along with another one made by GlaxoSmithKline. It is open to all and based at this hospital in Monrovia.
In the darkest days of the crisis here in Liberia, a senior doctor and nurse here at Redemption Hospital contracted Ebola virus disease, and they subsequently died. Many of the health care workers here became afraid to come to work and the hospital had to close for a time. In all, 13 members of the hospital staff died here.
DR. MARK KIEH, Redemption Hospital: It was scary. It was confusing
MILES O'BRIEN: DR. Mark Kieh is the site physician for the trial.
So far, there are 1, 500 volunteers. He is carefully watching them for side effects. So far, so good.
DR. MARK KIEH: Those we have seen are expected side effects of fever, muscle pain, pain at the injection sites, some joint22 pain, some — few people with rashes that resolve over time.
MILES O'BRIEN: The trial is run by Liberia's Ministry of Health and the U.S. National Institute of Allergy23 and Infectious Disease.
DR. ANTHONY FAUCI, Director, National Institute of Allergy and Infectious Diseases: At least in the most recent patient that we took care of, that that's about as sick as you can get without dying.
MILES O'BRIEN: On March 14, 2015, he suited up to treat a U.S. health care worker who became infected in Sierra Leone, and was airlifted to the NIH hospital outside Washington, where he received the highest level of intensive care possible. It kept him alive while his body mounted its own defense14.
It was touch and go for a week, but he survived.
DR. ANTHONY FAUCI: All of the people who have recovered from Ebola, even those who have been very ill, it was their immune system that ultimately suppressed and eliminated the virus.
MILES O'BRIEN: This is why Fauci and others are optimistic they have a found a way to stop Ebola its tracks. The human body can create the antibodies to fight off Ebola, but usually not fast enough.
An effective vaccine creates an army of Ebola antibodies that can stop the virus before it stampedes through the body. But here is the ironic25 rub.
DR. THOMAS FRIEDEN, Director, Centers for Disease Control and Prevention: If we are successful in controlling Ebola, we won't be successful in determining whether the vaccines26 are effective at preventing Ebola.
MILES O'BRIEN: Dr. Tom Frieden is director of the CDC. Ebola cases in Liberia are now at zero, and Sierra Leone is close behind.
If no one is getting Ebola, you can't tell for sure if the vaccine is protective, so they have to rely on other evidence.
DR. THOMAS FRIEDEN: So, the trials under way now will at least tell us whether they're safe, and they will tell us whether they lead to an immune reaction.
We wish we were further along with the vaccine, but it's very difficult to do research in the middle of an epidemic.
MILES O'BRIEN: In Freetown, pharmacist Morrison Jusu is among those who scrambled27 to get this trial under way at all. He is anxious to know if the hard work will pay off.
MORRISON JUSU: We are really looking forward to it being successful, so that someday in the future, we will be able to say, yes, I was a part of that team and I contributed. So, it will be a great feeling then.
MILES O'BRIEN: The answer will have to wait, but no one doubts the vaccine will meet its viral foe28 someday.
Miles O'Brien, the PBS NewsHour, Freetown, Sierra Leone.
点击收听单词发音
1 vaccine | |
n.牛痘苗,疫苗;adj.牛痘的,疫苗的 | |
参考例句: |
|
|
2 thawed | |
解冻 | |
参考例句: |
|
|
3 potency | |
n. 效力,潜能 | |
参考例句: |
|
|
4 timing | |
n.时间安排,时间选择 | |
参考例句: |
|
|
5 reminder | |
n.提醒物,纪念品;暗示,提示 | |
参考例句: |
|
|
6 high-tech | |
adj.高科技的 | |
参考例句: |
|
|
7 generators | |
n.发电机,发生器( generator的名词复数 );电力公司 | |
参考例句: |
|
|
8 Fahrenheit | |
n./adj.华氏温度;华氏温度计(的) | |
参考例句: |
|
|
9 essentially | |
adv.本质上,实质上,基本上 | |
参考例句: |
|
|
10 rumors | |
n.传闻( rumor的名词复数 );[古]名誉;咕哝;[古]喧嚷v.传闻( rumor的第三人称单数 );[古]名誉;咕哝;[古]喧嚷 | |
参考例句: |
|
|
11 uncertainties | |
无把握( uncertainty的名词复数 ); 不确定; 变化不定; 无把握、不确定的事物 | |
参考例句: |
|
|
12 investigators | |
n.调查者,审查者( investigator的名词复数 ) | |
参考例句: |
|
|
13 allied | |
adj.协约国的;同盟国的 | |
参考例句: |
|
|
14 defense | |
n.防御,保卫;[pl.]防务工事;辩护,答辩 | |
参考例句: |
|
|
15 recipient | |
a.接受的,感受性强的 n.接受者,感受者,容器 | |
参考例句: |
|
|
16 epidemic | |
n.流行病;盛行;adj.流行性的,流传极广的 | |
参考例句: |
|
|
17 decided | |
adj.决定了的,坚决的;明显的,明确的 | |
参考例句: |
|
|
18 contagious | |
adj.传染性的,有感染力的 | |
参考例句: |
|
|
19 shunned | |
v.避开,回避,避免( shun的过去式和过去分词 ) | |
参考例句: |
|
|
20 partnership | |
n.合作关系,伙伴关系 | |
参考例句: |
|
|
21 ministry | |
n.(政府的)部;牧师 | |
参考例句: |
|
|
22 joint | |
adj.联合的,共同的;n.关节,接合处;v.连接,贴合 | |
参考例句: |
|
|
23 allergy | |
n.(因食物、药物等而引起的)过敏症 | |
参考例句: |
|
|
24 ravages | |
劫掠后的残迹,破坏的结果,毁坏后的残迹 | |
参考例句: |
|
|
25 ironic | |
adj.讽刺的,有讽刺意味的,出乎意料的 | |
参考例句: |
|
|
26 vaccines | |
疫苗,痘苗( vaccine的名词复数 ) | |
参考例句: |
|
|
27 scrambled | |
v.快速爬行( scramble的过去式和过去分词 );攀登;争夺;(军事飞机)紧急起飞 | |
参考例句: |
|
|
28 foe | |
n.敌人,仇敌 | |
参考例句: |
|
|